Analyst Reco. Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
5.47 ^USD	+4.99%		+2.24%	-46.00%

05-01	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	MT
03-13	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	02-29	MT
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	01-03	MT
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating	12-12	MT
Citigroup Upgrades Editas Medicine to Buy From Neutral, Price Target is $11	23-10-24	MT
ANALYST RECOMMENDATIONS : Dollar General, On Holding, Rio Tinto, Solaredge, Thermo Fisher...	23-10-24
JPMorgan Upgrades Editas Medicine to Neutral From Underweight, Price Target is $8	23-10-18	MT
Stifel Upgrades Editas Medicine to Buy From Hold, Adjusts Price Target to $17 From $9	23-09-29	MT
Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating	23-08-03	MT
Raymond James Upgrades Editas Medicine to Outperform From Market Perform, Price Target is $17	23-06-13	MT
Credit Suisse Trims Editas Medicine's Price Target to $14 From $15, Keeps Neutral Rating	23-05-08	MT
RBC Lifts Price Target on Editas Medicine to $8 From $7, Maintains Sector Perform, Speculative Risk	23-05-08	MT
RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating	23-04-06	MT
Credit Suisse Raises Editas Medicine's Price Target to $15 From $13, Keeps Neutral Rating	23-02-23	MT
Chardan Adjusts Price Target on Editas Medicine to $22 From $35, Maintains Buy Rating	23-02-23	MT
Cantor Fitzgerald Starts Editas Medicine at Overweight With $15 Price Target	23-02-01	MT
Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight Rating	23-01-24	MT
SVB Securities Adjusts Price Target on Editas Medicine to $7 From $6, Maintains Market Perform Rating	23-01-23	MT
SVB Securities Trims Price Target on Editas Medicine to $6 From $7, Maintains Market Perform Rating	23-01-10	MT
Wells Fargo Adjusts Price Target on Editas Medicine to $36 From $50, Maintains Overweight Rating	23-01-04	MT
Citigroup Initiates Coverage on Editas Medicine With Neutral Rating, $11 Price Target	22-12-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Analyst Reco.

Filters